

# SmartPA Criteria Proposal

|                                   |  |
|-----------------------------------|--|
| <b>Drug/Drug Class:</b>           | Serotonin and Norepinephrine Reuptake Inhibitors (SNRI)<br>Clinical Edit   |
| <b>First Implementation Date:</b> | November 18, 2010  |
| <b>Proposed Date:</b>             | June 16, 2022  |
| <b>Prepared for:</b>              | MO HealthNet   |
| <b>Prepared by:</b>               | MO HealthNet/Conduent  |
| <b>Criteria Status:</b>           | <input type="checkbox"/> Existing Criteria<br><input checked="" type="checkbox"/> Revision of Existing Criteria<br><input type="checkbox"/> New Criteria |

## Executive Summary

**Purpose:** Ensure appropriate utilization and control of serotonin-norepinephrine reuptake inhibitor (SNRI) agents

**Why Issue Selected:** MO HealthNet will assess the usage of SNRI agents in the pharmacy program with a primary goal of patient safety. Participants may have multiple prescribers and/or multiple pharmacies caring for them, and without a clinical edit it is almost impossible to prevent duplication within a drug class, dangerous drug interactions, or overmedication. By using medical evidence guidelines, this clinical edit can flag potentially dangerous duplicate and high dose therapy for SNRI agents. The edit helps to provide an “early warning alert” to the pharmacist filling the prescription and the prescribing physician. As always, if a provider wishes to override a denial for medically necessary reasons, a claim can be approved with further medical input through direct communication with the MHD Hotline.

### Program-Specific Information:

| Date Range FFS 4-1-2021 to 3-31-2022 |                                |        |                |                     |
|--------------------------------------|--------------------------------|--------|----------------|---------------------|
| Generic Equivalent                   | Drug Description               | Claims | Spend          | Avg Spend per Claim |
| DESVENLAFAXINE                       | DESVENLAFAXINE ER 50 MG TAB    | 107    | \$12,755.38    | \$120.12            |
|                                      | DESVENLAFAXINE ER 100 MG TAB   | 169    | \$21,845.49    | \$129.08            |
|                                      | PRISTIQ ER 25 MG TABLET        | 1,668  | \$54,274.22    | \$32.50             |
|                                      | PRISTIQ ER 50 MG TABLET        | 5,626  | \$172,342.04   | \$30.50             |
|                                      | PRISTIQ ER 100 MG TABLET       | 6,099  | \$195,354.56   | \$31.96             |
| DULOXETINE                           | CYMBALTA 20 MG CAPSULE         | 6,304  | \$109,201.80   | \$17.31             |
|                                      | CYMBALTA 30 MG CAPSULE         | 34,609 | \$581,061.69   | \$16.77             |
|                                      | CYMBALTA 60 MG CAPSULE         | 61,493 | \$1,060,690.58 | \$17.23             |
|                                      | DRIZALMA SPRINKLE DR 20 MG CAP | 2      | \$214.31       | \$107.16            |
|                                      | DRIZALMA SPRINKLE DR 30 MG CAP | 13     | \$2,616.53     | \$202.85            |
|                                      | DRIZALMA SPRINKLE DR 40 MG CAP | 0      | -              | -                   |
|                                      | DRIZALMA SPRINKLE DR 60 MG CAP | 29     | \$6,177.09     | \$215.08            |
|                                      | IRENKA DR 40 MG CAPSULE        | 893    | \$80,352.85    | \$88.96             |
| LEVOMILNACIPRAN                      | FETZIMA ER 20 MG CAPSULE       | 260    | \$143,066.01   | \$554.29            |
|                                      | FETZIMA ER 40 MG CAPSULE       | 416    | \$187,962.24   | \$451.51            |
|                                      | FETZIMA ER 80 MG CAPSULE       | 409    | \$162,179.88   | \$397.32            |
|                                      | FETZIMA ER 120 MG CAPSULE      | 554    | \$226,850.10   | \$410.42            |
|                                      | FETZIMA 20-40 MG TITRATION PAK | 8      | \$2,760.30     | \$386.65            |
| MILNACIPRAN                          | SAVELLA 12.5 MG TABLET         | 31     | \$9,183.66     | \$287.13            |
|                                      | SAVELLA 25 MG TABLET           | 104    | \$46,722.36    | \$449.23            |
|                                      | SAVELLA 50 MG TABLET           | 511    | \$184,719.28   | \$362.03            |

### SmartPA Clinical Proposal Form

© 2022 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

|                |                                |                |                       |                |
|----------------|--------------------------------|----------------|-----------------------|----------------|
|                | SAVELLA 100 MG TABLET          | 474            | \$181,685.62          | \$383.15       |
|                | SAVELLA TITRATION PACK         | 29             | \$10,357.93           | \$327.24       |
| VENLAFAXINE    | EFFEXOR 25 MG TABLET           | 349            | \$6,340.90            | \$18.25        |
|                | EFFEXOR 37.5MG TABLET          | 1,638          | \$25,702.18           | \$15.63        |
|                | EFFEXOR 50MG TABLET            | 380            | \$7,316.20            | \$19.20        |
|                | EFFEXOR 75MG TABLET            | 2,924          | \$49,162.94           | \$16.80        |
|                | EFFEXOR 100MG TABLET           | 853            | \$16,039.65           | \$18.77        |
| VENLAFAXINE ER | VENLAFAXINE HCL ER 37.5 MG TAB | 401            | \$47,204.08           | \$111.92       |
|                | VENLAFAXINE HCL ER 75 MG TAB   | 763            | \$63,813.85           | \$83.41        |
|                | VENLAFAXINE HCL ER 150 MG TAB  | 1,359          | \$128,713.83          | \$94.65        |
|                | VENLAFAXINE HCL ER 225 MG TAB  | 5,597          | \$681,076.22          | \$121.05       |
|                | EFFEXOR XR 37.5 MG CAPSULE     | 9,184          | \$143,460.91          | \$15.64        |
|                | EFFEXOR XR 75 MG CAPSULE       | 22,217         | \$348,831.27          | \$15.71        |
|                | EFFEXOR XR 150 MG CAPSULE      | 26,108         | \$449,991.13          | \$17.22        |
| <b>Total</b>   |                                | <b>191,581</b> | <b>\$5,420,027.08</b> | <b>\$28.29</b> |

Type of Criteria:  Increased risk of ADE  Preferred Drug List  
 Appropriate Indications  Clinical Edit

Data Sources:  Only Administrative Databases  Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Serotonin-norepinephrine reuptake inhibitor (SNRI) agents
- Age range: All appropriate MO HealthNet participants aged 5 years and older

## Approval Criteria

- Participant aged 5 years or older **AND**
- Documented compliance to current SNRI therapy regimen (90 days in the past 120 days) **OR**
- Documented appropriate diagnosis required for:
  - Participants < 18 years of age **OR**
  - Participants < 26 years of age who are also enrolled in foster care
- For diagnosis of major depressive disorder: all SNRI agents except Savella
- For diagnosis of fibromyalgia: duloxetine agents or Savella only
- For diagnosis of chronic musculoskeletal pain or diabetic peripheral neuropathic pain: duloxetine agents only
- For diagnosis of generalized anxiety disorder: duloxetine or venlafaxine agents only
- For diagnosis of social anxiety disorder, panic disorder, or migraine: venlafaxine agents only
- For Fetzima: documented therapeutic trial of generic Cymbalta or Effexor XR
- For venlafaxine HCL ER tablets and desvenlafaxine ER tablets: documented reason why participant cannot utilize generic Effexor XR capsules

## Denial Criteria

- Therapy will be denied if all approval criteria are not met
- Claim exceeds maximum dosage limits (see Appendix A)
- Participants < 18 years of age: history of > 2 SNRI agents for more than 30 days in the past 90 days
- Participants ≥ 18 years of age: history of > 2 SNRI agents for more than 60 days in the past 90 days
- Participant is on more than one SSRI agent and one SNRI agent concurrently for more than 30 days

SmartPA Clinical Proposal Form

© 2022 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

## Required Documentation

Laboratory Results:   
MedWatch Form:

Progress Notes:   
Other:

## Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)  
Rule Type: CE

## Default Approval Period

1 year

## Appendix A – Maximum Daily Dosage Limits

| Generic Equivalent | Max Daily Dose |
|--------------------|----------------|
| DESVENLAFAXINE     | 400 MG         |
| DULOXETINE         | 120 MG         |
| LEVOMILNACIPRAN    | 120 MG         |
| MILNACIPRAN        | 200 MG         |
| VENLAFAXINE        | 375 MG         |
| VENLAFAXINE ER     | 225 MG         |

| Drug Description               | Generic Equivalent | Dose Optimization Calculation                     |
|--------------------------------|--------------------|---|
| <b>CYMBALTA 20 MG</b>          | <b>DULOXETINE</b>  | <b>Deny dosing more frequently than 2 per day</b> |
| <b>CYMBALTA 30 MG</b>          | <b>DULOXETINE</b>  | <b>Deny dosing more frequently than 2 per day</b> |
| <b>CYMBALTA 60 MG</b>          | <b>DULOXETINE</b>  | <b>Deny dosing more frequently than 2 per day</b> |
| DESVENLAFAXINE ER 100MG        | DESVENLAFAXINE     | Deny dosing more frequently than 4 per day        |
| DESVENLAFAXINE ER 50MG         | DESVENLAFAXINE     | Deny dosing more frequently than 1 per day        |
| <b>DRIZALMA SPRINKLE 20 MG</b> | <b>DULOXETINE</b>  | <b>Deny dosing more frequently than 1 per day</b> |
| <b>DRIZALMA SPRINKLE 30 MG</b> | <b>DULOXETINE</b>  | <b>Deny dosing more frequently than 1 per day</b> |
| <b>DRIZALMA SPRINKLE 40 MG</b> | <b>DULOXETINE</b>  | <b>Deny dosing more frequently than 2 per day</b> |
| <b>DRIZALMA SPRINKLE 60 MG</b> | <b>DULOXETINE</b>  | <b>Deny dosing more frequently than 2 per day</b> |
| <b>DULOXETINE DR 40 MG</b>     | <b>DULOXETINE</b>  | <b>Deny dosing more frequently than 2 per day</b> |
| EFFEXOR XR 150 MG              | VENLAFAXINE        | Deny dosing more frequently than 2 per day        |
| EFFEXOR XR 37.5 MG             | VENLAFAXINE        | Deny dosing more frequently than 2 per day        |
| EFFEXOR XR 75 MG               | VENLAFAXINE        | Deny dosing more frequently than 3 per day        |
| PRISTIQ 100MG                  | DESVENLAFAXINE     | Deny dosing more frequently than 4 per day        |
| PRISTIQ 25MG                   | DESVENLAFAXINE     | Deny dosing more frequently than 1 per day        |
| PRISTIQ 50MG                   | DESVENLAFAXINE     | Deny dosing more frequently than 1 per day        |
| <b>SAVELLA 100 MG TABLET</b>   | <b>MILNACIPRAN</b> | <b>Deny dosing more frequently than 2 per day</b> |
| <b>SAVELLA 12.5 MG TABLET</b>  | <b>MILNACIPRAN</b> | <b>Deny dosing more frequently than 2 per day</b> |
| <b>SAVELLA 25 MG TABLET</b>    | <b>MILNACIPRAN</b> | <b>Deny dosing more frequently than 2 per day</b> |
| <b>SAVELLA 50 MG TABLET</b>    | <b>MILNACIPRAN</b> | <b>Deny dosing more frequently than 2 per day</b> |
| VENLAFAXINE ER 150 MG TAB      | VENLAFAXINE        | Deny dosing more frequently than 1 per day        |
| VENLAFAXINE ER 225 MG TAB      | VENLAFAXINE        | Deny dosing more frequently than 1 per day        |
| VENLAFAXINE ER 37.5 MG TAB     | VENLAFAXINE        | Deny dosing more frequently than 1 per day        |
| VENLAFAXINE ER 75 MG TAB       | VENLAFAXINE        | Deny dosing more frequently than 1 per day        |

SmartPA Clinical Proposal Form

© 2022 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

## References

- Facts & Comparisons. Serotonin and Norepinephrine Reuptake Inhibitors. Accessed May 9, 2022.

DRAFT